American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.
Treating Gastric Cancer by Targeting Notch and wnt-Beta-Catenin Cancer Stem-Cell Pathways
ASCO 2016 – GI
An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a γ-secretase inhibitor would be effective in treating patients with gastric cancer. Read More ›
NEO-102, an Anti-MUC5AC Monoclonal Antibody, in Chemotherapy-Refractory Metastatic Colorectal Cancer
ASCO 2016 – GI
Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer. Read More ›
Avelumab in Advanced Gastric or Gastroesophageal Cancer
ASCO 2016 – GI
Results from the phase 1b JAVELIN study of the anti–PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression. Read More ›
Nivolumab Monotherapy in Advanced Gastroesophageal or Gastric Cancer
ASCO 2016 – GI
Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer. Read More ›
Pembrolizumab in PD-L1+ Advanced Esophageal Carcinoma
ASCO 2016 – GI
Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma. Read More ›
The Role of the mTOR Pathway in Cancer Stem Cells in Esophageal Cancer
ASCO 2016 – GI
Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer. Read More ›
Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
ASCO 2016 – GI
Results from RAINBOW, a randomized phase 3 trial of the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Read More ›
Panitumumab in Wild-Type KRAS and RAS Metastatic Colorectal Cancer
ASCO 2016 – GI
Results from an open-label, randomized phase 3 trial evaluating the effects of panitumumab plus best supportive care versus best supportive care alone in chemorefractory, wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer. Read More ›

Page 23 of 33

Conference Coverage Proudly Presented by
American Health & Drug Benefits
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications


© Amplity, Inc. All Rights Reserved. Privacy Policy